Clinical trial · no report yet · Phase 1
LOTIS-7
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- NCT04970901 ↗
- Active, not recruiting
- ADC Therapeutics S.A.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 7 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- B-Cell Non-Hodgkin Lymphoma; Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Loncastuximab Tesirine; Polatuzumab Vedotin; Glofitamab; Mosunetuzumab; Obinutuzumab
- Arms
- Part 1 (Dose Escalation): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C) · Experimental
- Part 1 (Dose Escalation): Loncastuximab Tesirine + Glofitamab (Arm E) · Experimental
- Part 1 (Dose Escalation): Loncastuximab Tesirine + Mosunetuzumab (Arm F) · Experimental
- Part 2 (Dose Expansion): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C) · Experimental
- Part 2 (Dose Expansion): Loncastuximab Tesirine + Glofitamab (Arm E) · Experimental
- Part 2 (Dose Expansion): Loncastuximab Tesirine + Mosunetuzumab (Arm F) · Experimental
- Enrollment
- 154
- Primary outcomes
- Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
- Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Delay
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Interruption
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Reduction
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory Measurements
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Signs
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
- Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) Measurements
- Sponsor
- ADC Therapeutics S.A.
- Start
- Jun 17, 2022
- Primary completion
- Mar 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04970901 · updated Jul 17, 2026